Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A major new trial shows that targeting a systolic blood pressure below 120 mm Hg — rather than the standard 140 mm Hg — significantly cuts the risk of major cardiovascular events in stroke and TIA survivors. The OPTIMAL-STROKE trial, presented at the AHA Scientific Sessions and published in the NEJM, is the first adequately powered study to answer this question in this specific patient group. Renal side effects were slightly more common in the intensive treatment group, but serious adverse events were otherwise similar.
Going lower on blood pressure after stroke could save lives
For years, clinicians have been cautious about pushing blood pressure too low in stroke survivors, worried about compromising blood flow to the brain. The OPTIMAL-STROKE trial, presented at the American Heart Association Scientific Sessions and simultaneously published in The New England Journal of Medicine, offers a compelling reason to rethink that hesitation.
The multicenter Brazilian trial enrolled 4,368 patients with high blood pressure and a history of ischemic stroke or TIA. Participants were randomized to either an intensive systolic BP target of <120 mm Hg or a standard target of <140 mm Hg, and followed for a median of nearly 4 years. The intensive group saw meaningfully fewer major cardiovascular events — including CV death, nonfatal MI, nonfatal stroke, and hospitalizations for unstable angina or heart failure.
By the Numbers
Why it matters: This is the first trial adequately powered to test intensive BP control specifically in stroke/TIA patients — a group previously excluded from landmark studies like SPRINT. The findings could reshape post-stroke hypertension management guidelines and ease clinician concerns about aggressive BP lowering in this vulnerable population.
